SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire • Tuesday
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire • 12/17/24
ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire • 11/21/24
Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud ViolationsAccesswire • 11/20/24
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANAAccesswire • 11/19/24
Levi & Korsinsky Announces an Investigation on Behalf of Sana Biotechnology, Inc. (SANA) Shareholders Who May Have Been Affected by FraudAccesswire • 11/18/24
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– SANAAccesswire • 11/14/24
Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SANAAccesswire • 11/14/24
Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SANAAccesswire • 11/12/24
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a TurnaroundZacks Investment Research • 11/11/24
Sana Biotechnology, Inc. Being Investigated on Behalf of Sana Biotechnology, Inc. Investors. Contact Levi & Korsinsky For Details.Accesswire • 11/11/24
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business UpdatesGlobeNewsWire • 11/08/24
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025GlobeNewsWire • 11/04/24
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day ConferenceGlobeNewsWire • 09/30/24
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerGlobeNewsWire • 08/26/24